Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 11/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25207714 | 0.80 | MAPK14 (0.41) | MAPK14AAK1MAPK10CYP3A4 | |
| SCHEMBL15051277 | 0.80 | AAK1 (0.43) | PIK3C3MAPK14AAK1CYP3A4 | |
| SCHEMBL30365610 | 0.80 | MAPK14 (0.41) | MAPK14AAK1MAPK10CYP3A4 | |
| SCHEMBL25217236 | 0.77 | TGFBR1 (0.40) | MAPK14MAPK10 | |
| SCHEMBL30365434 | 0.77 | TGFBR1 (0.40) | MAPK14MAPK10 | |
| SCHEMBL15051361 | 0.76 | NR3C2 (0.42) | PIK3C3AAK1MAPK10CYP3A4 | |
| SCHEMBL2317159 | 0.76 | TDP1 (0.39) | — | |
| SCHEMBL15050234 | 0.76 | MAPK14 (0.41) | PIK3C3MAPK14AAK1MAPK10CYP3A4 | |
| SCHEMBL15050692 | 0.74 | AAK1 (0.41) | PIK3C3MAPK14AAK1MAPK10CYP3A4 | |
| SCHEMBL15051389 | 0.72 | MAPK14 (0.37) | PIK3C3MAPK14AAK1MAPK10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4188930-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-10-23 | — | — | EP | disclosed |
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-4188930-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | CYP11B2, SDHA, UGT2B7 | PIK3C3 1806/4885MAPK14 3249/4885AAK1 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.